Filing Flows › GeneDx Holdings (WGS) › Q3 2025
GeneDx Holdings (WGS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 28, 2025
GeneDx Holdings (WGS) reported revenue of $117M for the third quarter 2025 (Q3 2025), +52% from a year earlier and +14% from the quarter before. Operating margin was -2.8%, net loss $7.6M (6.5% of revenue).
GeneDx Holdings, Q3 2025: revenue $117M (+52% year over year), operating margin -2.8%, net loss $7.6M, operating cash flow $15.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $117M | +14% | +52% |
| Operating profit | −$3.3M | -136% | — |
| Net earnings | −$7.6M | -171% | — |
| Operating cash flow | $15.8M | +51% | — |
| Free cash flow | $9.6M | +19% | — |
What changed
Revenue was $116.7M in Q3 2025, up 52% year over year and up 14% from the previous quarter. Patients with third-party insurance was the largest line at 81% of revenue. Patients with third-party insurance added $35.5M year over year (up 60%), 89% of the total change.
Gross margin was 72.4%, up 10.2 points from a year earlier. Operating costs exceeded revenue by $3.3M, an operating margin of -2.8%. Operating expenses grew 58% against revenue growth of 52%. The fastest-growing cost line was Research & development (+70%). The quarter ended with a net loss of $7.6M, after a profit of $10.8M the previous quarter. Net interest and other expense of $4.1M was the main reason.
Operating cash flow was $15.8M. Non-cash charges added back $6.5M of depreciation and amortization and $10.6M of share-based compensation. Working capital and other items added $6.3M. Capital expenditures of $6.2M left free cash flow of $9.6M.
Questions
What was GeneDx Holdings' revenue in the third quarter 2025?
GeneDx Holdings (WGS) reported revenue of $117M for the third quarter 2025 (Q3 2025), +52% from a year earlier and +14% from the quarter before.
Was GeneDx Holdings profitable in the third quarter 2025?
Operating loss was $3.3M (-2.8% of revenue) and net loss $7.6M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.